Linden Thomas Advisory Services LLC Lowers Stake in Innospec Inc. (NASDAQ:IOSP)

Linden Thomas Advisory Services LLC reduced its stake in shares of Innospec Inc. (NASDAQ:IOSP) by 1.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,589 shares of the specialty chemicals company’s stock after selling 133 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Innospec were worth $1,428,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Sei Investments Co. raised its holdings in shares of Innospec by 8.7% in the third quarter. Sei Investments Co. now owns 128,506 shares of the specialty chemicals company’s stock valued at $13,133,000 after acquiring an additional 10,268 shares in the last quarter. AMG National Trust Bank bought a new stake in shares of Innospec in the third quarter valued at about $907,000. Assenagon Asset Management S.A. acquired a new position in shares of Innospec during the third quarter valued at about $1,207,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Innospec by 4.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 298,635 shares of the specialty chemicals company’s stock valued at $30,520,000 after acquiring an additional 12,135 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in shares of Innospec by 1.7% during the fourth quarter. Diversified Trust Co now owns 11,154 shares of the specialty chemicals company’s stock valued at $1,375,000 after acquiring an additional 185 shares in the last quarter. 96.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Innospec

In other news, Director Leslie J. Parrette acquired 410 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were acquired at an average price of $123.96 per share, with a total value of $50,823.60. Following the purchase, the director now directly owns 3,620 shares of the company’s stock, valued at $448,735.20. The purchase was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Leslie J. Parrette purchased 410 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average price of $123.96 per share, with a total value of $50,823.60. Following the purchase, the director now owns 3,620 shares of the company’s stock, valued at $448,735.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP David B. Jones sold 2,500 shares of Innospec stock in a transaction on Friday, March 1st. The shares were sold at an average price of $125.79, for a total transaction of $314,475.00. Following the completion of the sale, the senior vice president now directly owns 9,664 shares in the company, valued at approximately $1,215,634.56. The disclosure for this sale can be found here. Insiders have sold 36,500 shares of company stock valued at $4,532,959 in the last 90 days. 1.35% of the stock is currently owned by company insiders.

Innospec Stock Down 0.9 %

Shares of IOSP traded down $1.13 during mid-day trading on Wednesday, hitting $121.82. 14,809 shares of the company traded hands, compared to its average volume of 87,778. Innospec Inc. has a 1-year low of $91.74 and a 1-year high of $131.18. The company has a market capitalization of $3.04 billion, a PE ratio of 22.07 and a beta of 1.10. The business has a 50 day moving average of $124.31 and a 200 day moving average of $115.55.

Innospec (NASDAQ:IOSP) last issued its earnings results on Tuesday, February 13th. The specialty chemicals company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.59 by $0.25. The firm had revenue of $494.70 million for the quarter, compared to analyst estimates of $479.47 million. Innospec had a return on equity of 13.69% and a net margin of 7.14%. Innospec’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.20 earnings per share. As a group, research analysts expect that Innospec Inc. will post 6.77 EPS for the current fiscal year.

Innospec Profile

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in additives in diesel, jet, marine, fuel oil and other fuels.